Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients: A Multicenter Prospective Observational Study

Breast cancer is mainly formed in the tissues of the breast, and it spreads through the lymphatic system. They are mostly found in women rather than men. The breast cancer incidence has been increasing globally, with 1 in 8 women developing cancer in their lifetime. This prospective observational study was conducted to determine the Chemotherapy-Induced Nausea and Vomiting (CINV) in post-mastectomy breast cancer patients for nine months in a tertiary care hospital. Sixty patients were divided into two groups where one arm received Olanzapine, and the other received aprepitant. Both the arms were analysed for the severity of nausea and vomiting. Aprepitant (APT) is a neurokinin one receptor antagonist (NK1RA) which is used as antiemetic in the prophylaxis of CINV. Olanzapine (OLP) is a second-generation antipsychotic agent, which works by blocking the serotonin receptor. The objective of the study is to Evaluate the Safety and Efficacy of APT versus OLP in preventing CINV in breast cancer patients on Docetaxel-Adriamycin-Cyclophosphamide regimen. The OLP is more effective than APT in antiemetic therapy.

Download Full-text

Chemotherapy-Induced Nausea and Vomiting Breast Cancer Patients from a Chinese Multicenter Prospective Longitudinal Observational Study

10.20944/preprints202106.0064.v1 ◽

2021 ◽

Author(s):

Xin-Juan Huang ◽

Xu-Ying Li ◽

Lu Luo

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Observational Study ◽

Cancer Patients ◽

Nausea And Vomiting ◽

Breast Cancer Patients ◽

History Of ◽

Delayed Cinv ◽

Acute Cinv ◽

Prospective Longitudinal

Aims: To assess the occurrence of Chemotherapy-induced nausea and vomiting (CINV) after standard antiemetic therapy in the acute (24 h post-chemotherapy) and delayed (2–5 days post-chemotherapy) phases, as well as to identify risk factors for CINV in the acute and delayed phases. Methods: This prospective longitudinal and observational study analyzed the data of 400 breast cancer patients scheduled for chemotherapy over two cycles in two hospitals. The self-report survey was developed to assess the occurrence of CINV and their associated factors. CINV was evaluated with a Multinational Association of Supportive Care in Cancer Antiemetic Tool (MAT) on days 2 and 6 of chemotherapy. The incidence of acute and delayed CINV were presented by frequency and percentage. Generalized equation estimates (GEE) was used to identify risk factors of acute and delayed CINV. Results: There were 400 evaluable patients with complete Round 1 data, 334 for Round 2 data. Among 400 patients, 29.8% and 23.5% experienced acute and delayed CINV, respectively. Risk factors associated with for acute CINV were pain/insomnia, history of CINV, history of motion sickness (MS), and highly emetogenic chemotherapy regimen, while history of MS, CINV history, number of completed chemotherapy cycle number < 3, and the incidence of acute CINV were risk factors of delayed CINV (all p < 0.05). Conclusions: The findings may help nurses working for Chinese population in identifying patients at risk for CINV and in planning effective program to reduce the occurrence of CINV.

Download Full-text